US Supreme Court restores abortion pill access for now

The US Supreme Court has temporarily restored access to abortion pills nationwide by issuing a stay on a lower court's order. This order had reinstated an in-person dispensing requirement for mifepristone, a key drug in medication abortions. Louisiana had argued that mailing the drug interfered with its state-level abortion ban. The Supreme Court's decision, made on its emergency docket without explanation, will remain in effect while the justices consider whether to hear the case brought by mifepristone manufacturers. Mifepristone is widely available in states where abortion is legal, and its accessibility was previously expanded by the FDA.

The Supreme Court has preserved access to mifepristone, a widely used abortion pill, while a lawsuit challenging its availability proceeds. The court rejected lower-court restrictions that would have required in-person doctor visits and halted mail delivery of the drug. This decision allows women to continue obtaining mifepristone through pharmacies or mail, with access likely uninterrupted until at least next year. The justices granted emergency requests from mifepristone makers appealing a federal appeals court ruling. Justices Clarence Thomas and Samuel Alito dissented. Anti-abortion groups are seeking FDA restrictions on the drug, while the Republican administration states the review process takes time.

The US Supreme Court has allowed nationwide access to mail-order mifepristone, an abortion medication, to continue. In a 7-2 decision, the court sided against a Fifth Circuit ruling that had effectively banned the medication's mail delivery nationwide. Louisiana had sued the FDA, arguing the remote prescribing rules interfered with its state abortion ban. The Supreme Court found Louisiana lacked standing to challenge the mail-order access, sending the case back to the Fifth Circuit. This decision preserves access to medication abortion, which accounts for about two-thirds of abortions in the US, despite ongoing legal challenges. Justices Thomas and Alito dissented, arguing the Comstock Act should apply to mifepristone.

The Supreme Court has temporarily preserved women's access to the abortion pill mifepristone, preventing restrictions imposed by a federal appeals court from taking effect until at least Thursday. Justice Samuel Alito issued the order, allowing the pill to continue being obtained via pharmacies or mail without an in-person doctor's visit while the Court considers the case. This legal challenge stems from a lawsuit filed by Louisiana, which seeks to roll back FDA regulations on mifepristone, arguing it undermines state abortion bans and questioning the drug's safety. Lower courts had previously favored Louisiana, suggesting mail and telehealth access should be suspended. Mifepristone, used in medication abortions which constituted nearly two-thirds of U.S. abortions in 2023, remains accessible for now.

The Supreme Court has temporarily restored broad access to the abortion pill mifepristone, blocking a lower court ruling that had restricted its availability. Justice Samuel Alito's order allows women to obtain the pill through pharmacies or mail without an in-person doctor's visit, practices that had been permitted for years. This decision remains in effect for one week while the court further considers the issue. The ruling is significant as medication abortions, often using mifepristone, are the most common method in the U.S. and have been used to circumvent abortion bans in some states. The case originated from a lawsuit challenging the FDA's rules on mifepristone prescription, questioning its safety and the policy's impact on state bans.

The US Supreme Court has temporarily lifted a ban on mail delivery of the abortion pill mifepristone, restoring telehealth access for at least one week. Justice Samuel Alito issued an administrative stay, pausing a lower court's decision that would have required an in-person visit to obtain the medication. This action allows the Supreme Court more time to consider emergency requests from mifepristone manufacturers while legal challenges to the drug's accessibility continue. The case stems from a challenge by Louisiana and other Republican-led states. The court's decision comes as the contentious issue of abortion access is again before the justices, with a deadline for responses set for Thursday and the administrative stay expiring May 11.

The US Supreme Court has temporarily restored broad access to the abortion pill mifepristone, blocking a lower court ruling that had imposed new restrictions. Justice Samuel Alito issued an order allowing women to obtain the pill via pharmacies or mail, reinstating rules that had been in place for years. This decision comes after a federal appeals court had limited access, following a lawsuit by Louisiana seeking to restrict the drug's availability and undermine its state ban. Mifepristone, often used with another drug, is a primary method for abortions in the US and its accessibility has been a key factor in navigating state-level abortion bans. The Supreme Court's order will remain in effect for a week while it further considers the issue.

The Supreme Court has temporarily restored broad access to the abortion pill mifepristone, blocking a lower court ruling that had sought to impose new restrictions. Justice Samuel Alito signed the order, allowing women to obtain the pill via pharmacies or mail without an in-person doctor's visit, reinstating rules that had been in place for years. This decision comes after a federal appeals court had previously limited access to the medication. Mifepristone, often used in combination with another drug, is a primary method for medication abortions in the United States. The lawsuit originated from Louisiana, which argued that the pill's availability conflicted with its state-level abortion ban.

A US appeals court has limited mail-order access to the abortion pill mifepristone, overriding a lower court's pause on the case. The Supreme Court had previously rejected an effort to restrict the drug's access in 2024, but this new ruling allows for further review of FDA regulations. Proponents of the decision, like Louisiana's Attorney General, argue it protects unborn fetuses, while opponents, such as the ACLU and New York's Attorney General, contend it restricts vital healthcare, particularly for those in rural areas or with disabilities. Mifepristone, approved in 2000 and later expanded for use up to 10 weeks of pregnancy, works by blocking progesterone. It is also used for miscarriage management and Cushing syndrome.